Galapagos (GLPG)
(Delayed Data from NSDQ)
$27.00 USD
-0.02 (-0.07%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $27.01 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Galapagos NV [GLPG]
Reports for Purchase
Showing records 21 - 27 ( 27 total )
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
MANTA May Not Have Been the FDA Mantra After All
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
ROCELLA Is Off to a Running Start; GLPG1972 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
IPF in Vogue With Multiple Phase 3''s: Overview and Perspectives
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
IPF in Vogue With Multiple Phase 3''s: Overview and Perspectives
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Post-FINCH the Story Is Centered on Maturing Pipeline and Timing of Regulatory Filings With a Slew of Events During 2H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
May the Force Be With Filgotinib; Raising Target to $150
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Looking Beyond Filgotinib: Initiating on a High-Risk, Higher- Reward Pipeline Story With a Buy Rating and $136 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D